Home
Search

Letters, Testimony & Comments

BIO submits letters, testimony, and comments to government and regulatory bodies throughout the United States and around the world.

Featured Letters, Testimony, & Comments
CSBA Letter to Congressional Leaders on PBM, PPRV…
Dear Congressional Leaders:On behalf of the Council of State Bioscience Associations (CSBA)—a national coalition of independent, state and territory-based organizations representing the full breadth of America’s biotechnology ecosystem—we write to…
Learn more
BIO's Comments on Advisory Committee on…
Re: Docket No. CDC-2025-0783; Advisory Committee on Immunization Practices (ACIP) MeetingDear Dr. Zadeh and Members of the ACIP:The Biotechnology Innovation Organization (BIO) appreciates the opportunity to provide comments to the Advisory Committee…
Learn more
Testimony of BIO President & CEO John F. Crowley…
Chairman Cassidy, Ranking Member Sanders, and distinguished Members of the Committee:Thank you for the opportunity to appear before you today on behalf of the Biotechnology Innovation Organization (BIO), which represents more than 1,000…
Learn more
All Letters, Testimony & Comments
  • Show All
Search
Results
BIO IES: Advanced Biofuel RVP EPW Letter 170612
June 12, 2017
On behalf of the advanced and cellulosic biofuel industry and our respective companies and organizations, we are writing to ask for your support for the Consumer and Fuel Retailer Choice Act (S. 517), which is scheduled to be marked up in the…
BIO IES: Advanced Biofuel RVP EPW letter 170612
June 12, 2017
On behalf of the advanced and cellulosic biofuel industry and our respective companies and organizations, we are writing to ask for your support for the Consumer and Fuel Retailer Choice Act (S. 517), which is scheduled to be marked up in the…
Advanced Biofuel RVP EPW letter 170612
June 12, 2017
On behalf of the advanced and cellulosic biofuel industry and our respective companies and organizations, we are writing to ask for your support for the Consumer and Fuel Retailer Choice Act (S. 517), which is scheduled to be marked up in the…
US Biotech Alliance Sends Letter to USTR on Modernizing NAFTA
June 12, 2017
The U.S. Biotech Crops Alliance appreciates the opportunity to provide comments in response to USTR’s Request for Comments on negotiating objectives regarding modernization of the North American Free Trade Agreement with Canada and Mexico (82 FR…
BIO Submits Comments to FDA on Enhancing Patient Engagement Efforts
June 12, 2017
The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on Enhancing Patient Engagement Efforts Across the Food and Drug Administration.
BIO Comments to USTR on Modernizing NAFTA
June 12, 2017
The Biotechnology Innovation Organization (BIO) appreciates the opportunity to respond to the U.S. Trade Representative’s (USTR) request for comments on negotiating objectives to modernize the North American Free Trade Agreement (NAFTA).  
GHG Benefits of the Consumer and Fuel Retailer Choice Act
June 7, 2017
BIO IES: GHG Benefits of the Consumer and Fuel Retailer Choice Act Over the next 10 years, summer use of E15 can save between 7 million and 10.4 million metric tons of CO2 equivalent GHG emissions. The savings are equal to taking 1.4 million to 2…
GHG Benefits of the Consumer and Fuel Retailer Choice Act
June 7, 2017
BIO IES: GHG Benefits of the Consumer and Fuel Retailer Choice Act Over the next 10 years, summer use of E15 can save between 7 million and 10.4 million metric tons of CO2 equivalent GHG emissions. The savings are equal to taking 1.4 million to 2…
BIO submits comments to USDA’s Animal and Plant Health Inspection Service RE: Availability of an Environmental Assessment for the Field Release of Genetically Engineered Diamondback Moths
May 25, 2017
May 19, 2017Docket No. APHIS-2014-0056Regulatory Analysis and DevelopmentPlant Protection Division - APHISStation 3A–03.84700 River Road Unit 118Riverdale, MD 20737–1238.http://www.regulations.gov/#!docketDetail;D=APHIS-2014-0056Re: Animal and Plant…
BIO Submits Comments Re: 340 B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties (CMP) Regulation Interim Final Rule
May 16, 2017
BIO submitted comments in response to the 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation Interim Final Rule (the "Interim Final Rule") published in the Federeal Register on March 20, 2017.In the balance…